TABLE 1.
Pre-Random Assignment Patient Characteristics
| Characteristic | All (n = 239) | Original Cohort (N = 370) | CT (n = 126) | CT + B (n = 113) | P |
|---|---|---|---|---|---|
| Age at enrollment, years, mean ± SD | 64.99 ± 10.72 | 64.5 ± 10.3 | 65.32 ± 10.60 | 64.62 ± 10.89 | .617 |
| Sex, No. (%) | .342 | ||||
| Female | 90 (37.66) | 147 (39.73) | 51 (40.48) | 39 (34.51) | |
| Male | 149 (62.34) | 223 (60.27) | 75 (59.52) | 74 (65.49) | |
| Study arm, No. (%) | |||||
| CT | 126 (52.72) | 194 (52.43) | |||
| CT + B | 113 (47.28) | 176 (47.57) | |||
| CT regimen, No. (%) | .906 | ||||
| FOLFOX4 | 145 (60.67) | 221 (59.73) | 76 (60.32) | 69 (61.06) | |
| FOLFIRI | 94 (39.33) | 149 (40.27) | 50 (39.68) | 44 (38.94) | |
| KRAS status, No. (%) | .748 | ||||
| Wt | 154 (64.44) | 235 (63.51) | 80 (63.49) | 74 (65.49) | |
| Mut | 85 (35.56) | 135 (36.49) | 46 (36.51) | 39 (34.51) | |
| Tumor localization, No. (%) | .124 | ||||
| Rectum | 64 (26.78) | 92 (24.86) | 39 (30.95) | 25 (22.12) | |
| Colon | 175 (73.22) | 278 (75.14) | 87 (69.05) | 88 (77.88) | |
| ECOG PS, No. (%) | .156 | ||||
| 0 | 194 (81.17) | 298 (80.54) | 98 (77.78) | 96 (84.96) | |
| ≥1 | 45 (18.83) | 72 (19.46) | 28 (22.22) | 17 (15.04) | |
| Stage at diagnosis,a No. (%) | .743 | ||||
| I-III | 54 (23.68) | 90 (26.24) | 29 (24.58) | 20 (21.51) | |
| IV | 174 (76.32) | 253 (73.76) | 89 (75.42) | 73 (78.49) |
Abbreviations: B, bevacizumab; CT, chemotherapy; CT + B, chemotherapy + bevacizumab; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOX4, fluorouracil, leucovorin, and oxaliplatin; SD, standard deviation.
a
The sum does not add to the total because of missing data.